03:30 PM EDT, 06/03/2025 (MT Newswires) -- Immix Biopharma ( IMMX ) said the US multisite clinical trial evaluating its NXC-201 cell therapy in relapsed or refractory AL Amyloidosis achieved its primary endpoint of complete response.

NXC-201 treatment resulted in a 70% complete response rate, and all of the patients in the trial had baseline relapsed or refractory AL Amyloidosis organ involvement, the company said Tuesday in a statement.

The company plans to submit a biologics license application for approval from the Food and Drug Administration.

The interim results of the Phase 1/2 study were presented at a clinical oncology conference in Chicago.

Price: 2.05, Change: -0.55, Percent Change: -21.15